A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma.
Dr. Sandy Srinivas
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|